^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Marabex (MAGE-A3 vaccine)

i
Other names: MG1-MAGEA3, Ad MAGEA3, MG1 MA3, Ad-MG1-MAGEA3, MAGE-A3 vaccine, MG1MA3, MG1 Maraba/MAGE-A3
Company:
AbbVie, Turnstone Biologics
Drug class:
MAGE-A3 modulator
9ms
MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours (clinicaltrials.gov)
P1/2, N=56, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date • Metastases
|
PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
|
EGFR mutation • ALK mutation
|
Marabex (MAGE-A3 vaccine)
over1year
MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours (clinicaltrials.gov)
P1/2, N=56, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2023 --> Dec 2023
Trial completion date • Metastases
|
PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
|
EGFR mutation • ALK mutation
|
Marabex (MAGE-A3 vaccine)
almost2years
MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours (clinicaltrials.gov)
P1/2, N=56, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2022 --> Jun 2023
Trial completion date • Metastases
|
PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
|
EGFR mutation • ALK mutation
|
Marabex (MAGE-A3 vaccine)
4years
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients (clinicaltrials.gov)
P1/2, N=16, Completed, Turnstone Biologics, Corp. | Active, not recruiting --> Completed | N=75 --> 16 | Trial completion date: Aug 2021 --> May 2020
Clinical • Trial completion • Enrollment change • Trial completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MAGEA3 (MAGE Family Member A3)
|
EGFR mutation • ALK translocation
|
Keytruda (pembrolizumab) • Marabex (MAGE-A3 vaccine)